– USA, TN – Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced the appointments of Perry Sternberg and Dr. Marty Makary (M.D., M.P.H.) to its Board of Directors, effective immediately.
The Company also announced the resignation of Bob Kammer from the Board of Directors, effective immediately.
“It is a pleasure to welcome Perry and Marty, two extraordinarily accomplished professionals, to the Harrow Health Board of Directors,” said Chairman and CEO, Mark Baum.
He added, “Perry’s repeated commercial success as a senior executive at multiple leading eyecare companies, specifically his expertise in developing and implementing strategic marketing and tactical sales plans that drive revenue growth of ophthalmic pharmaceuticals, will be of great value to Harrow as we expand our platform to include more FDA‑approved products, such as AMP-100, which, if approved, we expect to launch within the next 12 months. Likewise, Dr. Makary’s extensive experience as a surgeon, corporate advisor, and policy thought leader, and his research into vulnerable populations and access to healthcare, align with our mission to make medicines accessible and affordable for all Americans. We look forward to the valuable perspectives, creative and strategic thinking, and strong governance that each will contribute as we continue to advance our twin goals of making Harrow Health a leading U.S. eyecare company and building value for Harrow’s shareholders.”
About Perry J. Sternberg
Perry Sternberg serves as President and CEO of Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system therapies. Before joining Corium, he served as EVP and Head of U.S. Commercial for Shire Plc’s ophthalmology business unit as well as six other Shire business units, which, during his tenure, in the aggregate, generated more than $8 billion in annual revenue. Sternberg also served as CCO and Global Head of Shire’s CNS Business. Of note, Sternberg was a leader on the team responsible for Shire’s 2013 acquisition of Xiidra™ as a development-stage drug candidate, which subsequently received FDA approval, was commercialized under his leadership, and ultimately sold, in 2019, for more than $5 billion. Sternberg previously served as VP and GM, the U.S. and Canada Pharmaceuticals at Bausch + Lomb, as well as various leadership roles at Novartis Ophthalmics, Novartis Pharmaceuticals, and Merck & Co., Inc. In his 25 years of experience in biotechnology and pharmaceuticals, Sternberg has had direct responsibility for the launch and commercialization of more than 20 products across a wide range of therapeutic areas in diverse markets, including ophthalmic pharmaceuticals.
About Dr. Marty Makary
Dr. Marty Makary is a healthcare expert and serves as Chief of Islet Transplant Surgery at Johns Hopkins. Makary is a frequent public policy expert in the media and a leading voice for physicians, writing for The Wall Street Journal. He is the author of two New York Times bestselling books on healthcare and has published over 250 scientific peer-reviewed articles, including articles on organizational culture, surgical innovation, vulnerable populations, and the re-design of healthcare delivery. Makary has served in leadership at the World Health Organization and has been elected to the National Academy of Medicine. Makary has been a visiting professor at over 25 medical schools and is the recipient of the Nobility in Science Award from the National Pancreas Foundation. Makary speaks frequently on the future of healthcare and what it means for everyday Americans, business leaders, and healthcare professionals. His current research focuses on the appropriateness of medical care and the impact of the healthcare cost crisis on low-income populations. His newest book, The Price We Pay, tells the stories of healthcare’s disruptive innovators and the new movement to restore medicine to its mission.
About Harrow Health
Harrow Health, Inc. is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic vision care. Harrow Health also holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals.
For more information: https://www.harrowinc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.